



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Kevin E. Noonan
McDonnell Boehnen Hulbert & Berthoff
300 South Wacker Drive
Chicago, IL 60606

In Re: Patent Term Extension
Application for
U.S. Patent No. 6,395,767

APR 29 2013

Dear Mr. Noonan:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 6,395,767 for a period of 895 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website:
<http://www.fda.gov/opacom/morechoices/fdaforms/default.html>
(<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: ONGLYZA® (saxagliptin
hydrochloride)
Docket No.: FDA-2010-E-0061

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 6,395,767
(45) ISSUED : May 28, 2002
(75) INVENTOR : Jeffrey A. Robl et al.
(73) PATENT OWNER : Bristol-Myers Squibb Company
(95) PRODUCT : ONGLYZA® (saxaglyptin hydrochloride)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 6,395,767 based upon the regulatory review of the product ONGLYZA® (saxaglyptin hydrochloride) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 895 days

from February 16, 2021, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156.



I have caused the seal of the United States Patent and Trademark Office to be affixed this 1st day of April 2013.

Teresa Stanek Rea
Acting Under Secretary of Commerce for Intellectual Property
and Acting Director of the United States Patent and Trademark
Office